GlobeNewswire by notified

Correction to Company Announcement No. 1 of January 3, 2023

Share

Company Announcement

COPENHAGEN, Denmark; January 19, 2023Genmab A/S (Nasdaq:GMAB) Correction: In company announcement no. 1/2023 regarding transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons it was reported that member of the Board of Directors, Mijke Zachariasse,acquired a total of 175 shares in Genmab A/S due to vesting of restricted stock units (partly as employee of Genmab B.V., partly as board member). The correct number was a total of 297 shares inGenmab A/S.

In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons.

The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons.

About Genmab
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.

Contact:
Marisol Peron, Senior Vice President, Global Communications and Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

The Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-Fand other filingswith the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®;HexaBody in combination withthe HexaBody logo®; DuoHexaBody® and HexElect®.


CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

NNIT A/S: The Danish Business Authority has issued a decision requiring NNIT to update its accounting treatment of earn-out payments in the annual reports for 2020 and 202128.1.2023 17:18:54 CET | Press release

The Danish Business Authority has conducted a compliance review of NNIT A/S’ annual reports as stated in company announcement 12/2022. Following dialogue with NNIT, the Danish Business Authority has made a final decision affirming that the earn out payment related to the acquisition of Excellis Health Solutions should not be included in capitalized acquisition costs and goodwill, but instead expensed as remuneration as the earn out is in part subject to the selling shareholders’ continued employment during the accrual period. In consequence, NNIT is required to update its accounting treatment of earn-out payment in the annual reports from goodwill to special items as outlined below. A similar approach will be applied to the recognition of earn out payments for other acquisitions, including SCALES, Valiance Partner, HGP Group, SL Controls and prime4services. The technical changes to historical accounting policies will have no impact on total cash flow or the planned divestment of NNIT’s

Inside information: Digitalist Group’s subsidiary Digitalist Finland Oy has signed a term sheet for acquiring Walker & Handson Oy28.1.2023 13:00:00 CET | Press release

Digitalist Group Plc Inside information January 28nd, 2023 at 14:00 Inside information: Digitalist Group’s subsidiary Digitalist Finland Oy has signed a term sheet for acquiring Walker & Handson Oy Digitalist Group Plc (“Digitalist Group”) and its fully-owned subsidiary Digitalist Finland Oy have signed a term sheet (“LOI”) to an agreement (“Transaction”) in which Digitalist Finland Oy would acquire Walker & Handson Oy (“W&H”) to strengthen the management and tech & design business in Digitalist Finland Oy. In the intended Transaction Digitalist Finland Oy would acquire all shares in W&H through share exchange by issuing new Digitalist Finland Oy’s shares in a direct share issue to W&H representing approximately 10% of all shares in Digitalist Finland Oy after completion of the Transaction. The owner of W&H Jussi Hermunen will at the same time take over the position of Managing Director of Digitalist Finland Oy. Mr Jussi Hermunen would bring in solid experience of leading teams and bus

Hexagon Agility launches next generation Mobile Pipeline® modules with deliveries to Certarus28.1.2023 10:20:00 CET | Press release

28 January 2023: As previously disclosed, Hexagon Agility®, a business of Hexagon Composites, signed a multi-year agreement in March 2021 with Certarus, a leading full-service provider of bulk gas transport, to supply newly designed TITAN 450 Mobile Pipeline® modules. Hexagon Agility’s TITAN 450 modules represent the next generation of gas distribution modules and will be used to transport compressed and renewable natural gas (CNG/RNG) throughout North America. Under this agreement, Hexagon Agility has received a new USD 25.6 million (approx. NOK 253 million) order representing the inaugural order of Hexagon Agility’s new TITAN 450 modules. “We are proud to receive our first order for TITAN 450 from Certarus,” said Miguel Raimao, Vice President of Mobile Pipeline at Hexagon Agility. “Over 90% of the TITAN platform has been redesigned. The new TITAN 450 delivers 25% greater gas capacity, while being 20% lighter in the same 40-foot length. We appreciate our long-standing relationship wit

Brasilianska konkurrensmyndigheten godkänner försäljningen av Maha Energy Brasil27.1.2023 21:20:00 CET | Pressemelding

Maha Energy AB (publ) meddelar att brasilianska konkurrensmyndigheten (CADE) har, utan förbehåll, godkänt försäljningen av Maha Energy Brasil Ltda. till PetroRecôncavo S.A. Överlåtelseavtalet för försäljning av hela Mahas andel i Bolagets brasilianska dotterbolag offentliggjordes den 28 december och försäljningens genomförande villkorades av sedvanliga förbehåll, varav ett var godkännande av den brasilianska konkurrensmyndigheten. Denna information är sådan information som Maha Energy AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 27 januari, 2023 kl.21:20 CET För ytterligare information, kontakta: Paulo Thiago Mendonça, VD Telefon: +46 8 611 05 11 E-post: info@mahaenergy.ca Bernardo Guterres, CFO Telefon: +46 8 611 05 11 E-post: info@mahaenergy.ca Kort om Maha Maha Energy AB (publ) är ett listat, internationellt uppströmsolje- och gasbolag vars affärsverksamhet

Brazilian antitrust authority approves the sale of Maha Energy Brasil27.1.2023 21:20:00 CET | Press release

Maha Energy AB is pleased to announce that the Brazilian antitrust authority (CADE) has approved, without restrictions, the sale of Maha Energy Brasil Ltda. to PetroRecôncavo S.A. The quota purchase agreement for the sale of the entirety of Maha’s stake in its Brazilian subsidiary was announced on December 28, 2022, with its closing subject to other customary precedent conditions, the approval by the Brazilian antitrust authority being one of them. This information is such information as Maha Energy AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 21:20 CET, 27 January 2023 For more information, please contact: Paulo Thiago Mendonça, CEO Phone: +46 8 611 05 11 E-mail: info@mahaenergy.ca Bernardo Guterres, CFO Phone: +46 8 611 05 11 E-mail: info@mahaenergy.ca About Maha Maha Energy AB (publ) is a listed, international upstream oil and gas company whose